News
ICViewExpert PerspectivesMedical World NewsPathogen PlaybookVideosWebinars
Conference CoverageConference ListingAPIC Chapters
Infection Control TodaySupplements And Featured Publications
CME/CEEditorial Advisory BoardJob BoardPartnersSponsoredWhitepapers
Subscribe
Educator of the Year Official Rules2024 Educator of the Year Winner2023 Educator of the Year WinnerEducator of the Year
Advanced TechnologyAdvanced TechnologyAdvanced Technology
Bug of the Month
COVID-19
Environmental ServicesEnvironmental Services
HAIs
Hand Hygiene
IC Trends
Long-Term CareLong-Term Care
Operating Room
Personal Protective EquipmentPersonal Protective Equipment
Policy
PreventionPreventionPreventionPrevention
Sterile ProcessingSterile Processing
Surface Disinfection
Vascular Access
Spotlight -
  • IC Trends
  • Bug of the Month
  • Featured Articles
  • Featured Columns
  • Pathogen Playbook
Advanced TechnologyAdvanced TechnologyAdvanced Technology
Bug of the Month
COVID-19
Environmental ServicesEnvironmental Services
HAIs
Hand Hygiene
IC Trends
Long-Term CareLong-Term Care
Operating Room
Personal Protective EquipmentPersonal Protective Equipment
Policy
PreventionPreventionPreventionPrevention
Sterile ProcessingSterile Processing
Surface Disinfection
Vascular Access
    • News
    • Subscribe
Advertisement

Link Between Tuberculosis and Parkinson's Disease is Discovered

May 22, 2018
Article

The mechanism our immune cells use to clear bacterial infections like tuberculosis (TB) might also be implicated in Parkinson's disease, according to a new collaborative study led by the Francis Crick Institute, Newcastle University and GSK.

The findings, which will be published in The EMBO Journal, provide a possible explanation of the cause of Parkinson's disease and suggest that drugs designed to treat Parkinson's might work for TB, too.

The most common genetic mutation in Parkinson's disease patients is in a gene called LRRK2, which makes the LRRK2 protein overactive.

Drugs that block LRRK2 are a promising new treatment for Parkinson's, with many pharmaceutical companies developing drugs to target LRRK2 and clinical trials underway. But how overactive LRRK2 causes Parkinson's and why LRRK2 blockers work was a mystery.

The biological causes of Parkinson's remain largely unknown, making it more difficult to develop and improve treatments. Discovering a mechanism that causes Parkinson's and how drugs affect it could significantly advance efforts to improve treatments.

By studying what LRRK2 does in immune cells called macrophages that are infected with Mycobacterium tuberculosis (Mtb) -- the bacterium that causes TB -- researchers believe they have uncovered a potential cause of Parkinson's.

Macrophages recognise and engulf Mtb securing it within tight-fitting internal compartments called phagosomes. Another part of the cell called the lysosome then fuses with the phagosome to destroy the bacterium inside.

Using a combination of experimental approaches, Crick and GSK researchers, in collaboration with proteomics specialist Matthias Trost from Newcastle University, found that LRRK2 prevents phagosomes from fusing with lysosomes in both human and mouse macrophages, making them less efficient at clearing bacteria. Deleting the LRRK2 gene or treating the cells with an LRRK2 blocker significantly reduced levels of Mtb.

These findings in cells were supported by experiments in mice. When the researchers deleted the gene for LRRK2 in mice, they found that they exhibited an enhanced early immune response to TB infection, and had significantly lower levels of Mtb in their lungs than control mice up to two weeks after infection.

"We think that this mechanism might also be at play in Parkinson's disease, where abnormal masses of protein called 'Lewy bodies' build up in neurons in the brain and cause damage," said Susanne Herbst, joint first author of the paper and post-doctoral fellow at the Crick.

The team suspect that LRRK2 might be preventing immune cells in the brain from degrading cell debris properly, leading to a build-up of protein in neurons that disrupts their function.

Susanne added: "By studying TB, we have found a possible explanation for why LRRK2 mutations are a genetic risk factor for Parkinson's disease. It's exciting when different fields of research connect up in unexpected ways like this!"

Co-author Patrick Lewis, Associate Professor in Cellular and Molecular Neuroscience at the University of Reading, said: "The dogma in the Parkinson's field has been to focus almost exclusively on what is happening to neurons in the brain to make them degenerate. But over the last few years, there has been a growing appreciation of the integral role of other cells in the brain and particularly the immune system in keeping neurons healthy. This study reinforces why we should think more broadly about the events that cause neurodegeneration, and that some of the answers to Parkinson's disease might come from immunology."

The findings also suggest that LRRK2 inhibitors could be a powerful new way of combating TB, which kills 1.67 million people every year.

"Drug-resistant TB is a serious emerging problem, and boosting the body's own immune defence against TB is an important step in the battle against antibiotic resistant strains," said Max Gutierrez, Group Leader at the Crick and senior author of the paper.

"LRRK2 inhibiting drugs are already being developed to treat Parkinson's disease and we're trying to see if we can repurpose them as a potential new TB therapy. This should be relatively straightforward because TB infects the lungs, so the LRRK2 inhibitors wouldn't need to cross the blood-brain barrier like they do in Parkinson's disease."

Source: Francis Crick Institute

Recent Videos
DJ Shannon, MPH, CIC, VA-BC, FAPIC
Jordan Bastian, MPH, CIC, at APIC25
Jordan Bastian, MPH, CIC, at APIC25
Pathogen Playbook Presenter: Sharon Ward-Fore, BS, MS, MT(ASCP), CIC, FAPIC
Pathogen Playbook Presenter: Sharon Ward-Fore, BS, MS, MT(ASCP), CIC, FAPIC
Pathogen Playbook Presenter: Sharon Ward-Fore, BS, MS, MT(ASCP), CIC, FAPIC
Pathogen Playbook Presenter: Sharon Ward-Fore, BS, MS, MT(ASCP), CIC, FAPIC
Pathogen Playbook Presenter: Sharon Ward-Fore, BS, MS, MT(ASCP), CIC, FAPIC
Pathogen Playbook Presenter: Sharon Ward-Fore, BS, MS, MT(ASCP), CIC, FAPIC
Pathogen Playbook Presenter: Sharon Ward-Fore, BS, MS, MT(ASCP), CIC, FAPIC
Related Content

Operating room, surgical site infections   (Adobe Stock, Unknown)

The Next Frontier in Infection Control: AI-Driven Operating Rooms

Tori Whitacre Martonicz
Published: July 15th 2025 | Updated: July 15th 2025
Article

Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.


The doctor is injecting a vaccination into the arm of a little girl.   Adobe Stock 170524806 by pingpao

Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence

Tori Whitacre Martonicz
July 15th 2025
Article

New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.


The doctor is injecting a vaccination into the arm of a little girl.   Adobe Stock 170524806 by pingpao

No Link Found Between Aluminum in Vaccines and Chronic Disorders

Tori Whitacre Martonicz
July 14th 2025
Article

A Danish study of 1.2 million children found no increased risk of autoimmune, allergic, or neurodevelopmental disorders from aluminum in early childhood vaccines, helping close key safety evidence gaps.


Weekly Rounds with Infection Control Today

Weekly Rounds: Stretcher Contamination, Lumens 2.0, and More

July 14th 2025
Article

Take 5 minutes to catch up on Infection Control Today’s highlights for the week ending July 13, 2025.


CDC  (Adobe Stock, unknown)

CDC Urges Vigilance: New Recommendations for Monitoring and Testing H5N1 Exposures

Infection Control Today® Editorial Staff
July 11th 2025
Article

With avian influenza A(H5N1) infections surfacing in both animals and humans, the CDC has issued updated guidance calling for aggressive monitoring and targeted testing to contain the virus and protect public health.


IP LifeLine from Infection Control Today

IP LifeLine: Layoffs and the Evolving Job Market Landscape for Infection Preventionists

Brenna Doran, PhD, MA, ACC, CIC
July 11th 2025
Article

Infection preventionists, once hailed as indispensable during the pandemic, now face a sobering reality: budget pressures, hiring freezes, and layoffs are reshaping the field, leaving many IPs worried about their future and questioning their value within health care organizations.

Related Content

Operating room, surgical site infections   (Adobe Stock, Unknown)

The Next Frontier in Infection Control: AI-Driven Operating Rooms

Tori Whitacre Martonicz
Published: July 15th 2025 | Updated: July 15th 2025
Article

Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.


The doctor is injecting a vaccination into the arm of a little girl.   Adobe Stock 170524806 by pingpao

Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence

Tori Whitacre Martonicz
July 15th 2025
Article

New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.


The doctor is injecting a vaccination into the arm of a little girl.   Adobe Stock 170524806 by pingpao

No Link Found Between Aluminum in Vaccines and Chronic Disorders

Tori Whitacre Martonicz
July 14th 2025
Article

A Danish study of 1.2 million children found no increased risk of autoimmune, allergic, or neurodevelopmental disorders from aluminum in early childhood vaccines, helping close key safety evidence gaps.


Weekly Rounds with Infection Control Today

Weekly Rounds: Stretcher Contamination, Lumens 2.0, and More

July 14th 2025
Article

Take 5 minutes to catch up on Infection Control Today’s highlights for the week ending July 13, 2025.


CDC  (Adobe Stock, unknown)

CDC Urges Vigilance: New Recommendations for Monitoring and Testing H5N1 Exposures

Infection Control Today® Editorial Staff
July 11th 2025
Article

With avian influenza A(H5N1) infections surfacing in both animals and humans, the CDC has issued updated guidance calling for aggressive monitoring and targeted testing to contain the virus and protect public health.


IP LifeLine from Infection Control Today

IP LifeLine: Layoffs and the Evolving Job Market Landscape for Infection Preventionists

Brenna Doran, PhD, MA, ACC, CIC
July 11th 2025
Article

Infection preventionists, once hailed as indispensable during the pandemic, now face a sobering reality: budget pressures, hiring freezes, and layoffs are reshaping the field, leaving many IPs worried about their future and questioning their value within health care organizations.

Advertise
About Us
Editorial Board
Contact Us
Job Board
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.
Home
About Us
News